Biomacromolecules,
Journal Year:
2024,
Volume and Issue:
25(2), P. 541 - 563
Published: Jan. 19, 2024
Nanoformulation
of
active
payloads
or
pharmaceutical
ingredients
(APIs)
has
always
been
an
area
interest
to
achieve
targeted,
sustained,
and
efficacious
delivery.
Various
delivery
platforms
have
explored,
but
loading
APIs
challenging
because
the
chemical
structural
properties
these
molecules.
Polymersomes
made
from
amphiphilic
block
copolymers
(ABCPs)
shown
enormous
promise
as
a
tunable
API
platform
confer
multifold
advantages
over
lipid-based
systems.
For
example,
COVID
booster
vaccine
comprising
polymersomes
encapsulating
spike
protein
(ACM-001)
recently
completed
Phase
I
clinical
trial
provides
case
for
developing
safe
drug
products
based
on
ABCP
platforms.
However,
several
limitations
need
be
resolved
before
they
can
reach
their
full
potential.
In
this
Perspective,
we
would
like
highlight
such
aspects
requiring
further
development
translating
ABCP-based
proof
concept
viable
commercial
product.
Advanced Functional Materials,
Journal Year:
2023,
Volume and Issue:
34(43)
Published: Nov. 21, 2023
Abstract
Metal–organic
framework
(MOF)
materials
are
gaining
significant
interest
in
biomedical
research,
owing
to
their
high
porosity,
crystallinity,
and
structural
compositional
diversity.
Their
versatile
hybrid
organic/inorganic
chemistry
endows
MOFs
with
the
capacity
retain
organic
(drug)
molecules,
metals,
gases,
effectively
channel
electrons
photons,
survive
harsh
physiological
conditions
such
as
low
pH,
even
protect
sensitive
biomolecules.
Extensive
preclinical
research
has
been
carried
out
treat
several
pathologies
and,
recently,
integration
other
stents
implants
demonstrated
promising
performance
regenerative
medicine.
However,
there
remains
a
gap
between
MOF
translation
into
clinically
societally
relevant
medicinal
products.
Here,
intrinsic
features
of
outlined
suitability
specific
applications
detoxification,
drug
gas
delivery,
or
(combination)
therapy
platforms
is
discussed.
Furthermore,
examples
how
have
engineered
evaluated
different
medical
indications,
including
cancer,
microbial,
inflammatory
diseases
described.
Finally,
challenges
facing
clinic
critically
examined,
goal
establishing
directions
more
realistic
approaches
that
can
bridge
translational
MOF‐containing
(nano)materials.
RSC Advances,
Journal Year:
2023,
Volume and Issue:
13(31), P. 21345 - 21364
Published: Jan. 1, 2023
Nanoparticle-modified
hydrogels
exhibit
substantial
promise
in
the
realm
of
wound
healing,
with
their
ability
to
expedite
tissue
regeneration,
mitigate
infection
risks,
and
facilitate
enhanced
therapeutic
outcomes.
Chemical Reviews,
Journal Year:
2024,
Volume and Issue:
124(3), P. 929 - 1033
Published: Jan. 29, 2024
RNA-based
therapies
have
catalyzed
a
revolutionary
transformation
in
the
biomedical
landscape,
offering
unprecedented
potential
disease
prevention
and
treatment.
However,
despite
their
remarkable
achievements,
these
encounter
substantial
challenges
including
low
stability,
susceptibility
to
degradation
by
nucleases,
prominent
negative
charge,
thereby
hindering
further
development.
Chemically
modified
platforms
emerged
as
strategic
innovation,
focusing
on
precise
alterations
either
RNA
moieties
or
associated
delivery
vectors.
This
comprehensive
review
delves
into
platforms,
underscoring
significance
augmenting
performance
translational
prospects
of
therapeutics.
It
encompasses
an
in-depth
analysis
various
chemically
that
been
instrumental
propelling
therapeutics
toward
clinical
utility.
Moreover,
scrutinizes
rationale
behind
diverse
chemical
modification
techniques
aiming
at
optimizing
therapeutic
efficacy
molecules,
facilitating
robust
management.
Recent
empirical
studies
corroborating
enhancement
through
modifications
are
highlighted.
Conclusively,
we
offer
profound
insights
transformative
impact
drugs
delineates
prospective
trajectories
for
future
development
integration.
Angewandte Chemie International Edition,
Journal Year:
2023,
Volume and Issue:
62(44)
Published: Aug. 31, 2023
Abstract
Chimeric
Antigen
Receptor
(CAR)
T
cell
immunotherapy
is
revolutionizing
treatment
for
patients
suffering
from
B‐cell
lymphoma
(BL).
However,
the
current
method
of
CAR
production
complicated
and
expensive,
requiring
collection
patient
blood
to
enrich
population,
ex
vivo
engineering/activation,
quality
assessment
before
can
receive
treatment.
Herein
we
leverage
Spleen
Selective
ORgan
Targeted
(SORT)
Lipid
Nanoparticles
(LNPs)
produce
cells
in
situ
bypass
extensive
laborious
process
currently
used.
Optimized
SORT
LNPs
containing
10
%
18
:
1
PA
transfected
CD3+,
CD8+,
CD4+
wild‐type
mice.
delivered
Cre
recombinase
mRNA
encoding
reporter
mice
a
lymphoreplete
B
model
(respectively)
after
intravenous
injection
without
need
active
targeting
ligands.
Moreover,
increased
overall
survival
with
less
aggressive
form
lymphoma.
In
addition,
reduced
tumor
metastasis
liver
by
increasing
infiltrating
lymphocytes.
Overall,
these
results
offer
promising
alternative
pre‐clinical
potential
treat
hematological
malignancies.
Nature Communications,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: July 5, 2024
Abstract
Fully
targeted
mRNA
therapeutics
necessitate
simultaneous
organ-specific
accumulation
and
effective
translation.
Despite
some
progress,
delivery
systems
are
still
unable
to
fully
achieve
this.
Here,
we
reformulate
lipid
nanoparticles
(LNPs)
through
adjustments
in
material
structures
compositions
systematically
the
pulmonary
hepatic
(respectively)
distribution
expression.
A
combinatorial
library
of
degradable-core
based
ionizable
cationic
lipids
is
designed,
following
by
optimisation
LNP
compositions.
Contrary
current
paradigms,
our
findings
demonstrate
that
cholesterol
phospholipid
dispensable
for
functionality.
Specifically,
cholesterol-removal
addresses
persistent
challenge
preventing
nanoparticle
tissues.
By
modulating
simplifying
intrinsic
components,
concurrent
translation
achieved
lung
liver,
respectively.
This
targeting
strategy
applicable
existing
with
potential
expand
progress
precise
therapy
diverse
diseases.
Nature Communications,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: Feb. 29, 2024
Abstract
Lipid
nanoparticles
for
delivering
mRNA
therapeutics
hold
immense
promise
the
treatment
of
a
wide
range
lung-associated
diseases.
However,
lack
effective
methodologies
capable
identifying
pulmonary
delivery
profile
chemically
distinct
lipid
libraries
poses
significant
obstacle
to
advancement
therapeutics.
Here
we
report
implementation
barcoded
high-throughput
screening
system
as
means
identify
lung-targeting
efficacy
cationic,
degradable
lipid-like
materials.
We
combinatorially
synthesize
180
lipids
which
are
initially
screened
in
vitro.
then
use
barcoding
technology
quantify
how
selected
96
deliver
DNA
barcodes
vivo.
The
top-performing
nanoparticle
formulation
Cas9-based
genetic
editors
exhibits
therapeutic
potential
antiangiogenic
cancer
therapy
within
lung
tumor
model
female
mice.
These
data
demonstrate
that
employing
tool
with
tropism
holds
development
next-generation
extrahepatic
platforms.
Nature Communications,
Journal Year:
2023,
Volume and Issue:
14(1)
Published: Nov. 11, 2023
Pro-tumoral
macrophages
in
lung
tumors
present
a
significant
challenge
immunotherapy.
Here,
we
introduce
pH-responsive
nanomedicine
approach
for
activating
anti-tumoral
and
dendritic
cells.
Using
layered
double
hydroxide
nanosheet
carrier,
co-deliver
T-type
calcium
channel
inhibitor
(TTA-Q6)
CD47
(RRX-001)
into
tumors.
In
the
tumor
acidic
environment,
TTA-Q6
is
released,
disrupting
cancer
cell
uptake,
causing
endoplasmic
reticulum
stress
inducing
calreticulin
transfer
to
surface.
Surface
activates
triggers
maturation,
promoting
effective
antigen
presentation
therefore
antitumor
T
Simultaneously,
RRX-001
reduces
protein
levels,
aiding
preventing
immune
escape
by
calreticulin-rich
models
male
mice,
this
combined
shows
anti-tumor
effects
immunity
against
re-exposure,
highlighting
its
potential
MedComm – Oncology,
Journal Year:
2024,
Volume and Issue:
3(1)
Published: March 1, 2024
Abstract
Rapid
growth
in
nanoparticles
(NPs)
as
delivery
systems
holds
vast
promise
to
promote
therapeutic
approaches
for
cancer
treatment.
Presently,
a
diverse
array
of
NPs
with
unique
properties
have
been
developed
overcome
different
challenges
and
achieve
sophisticated
routes
enhancement
series
therapies.
Inspiring
advances
achieved
the
field
therapy
using
NPs.
In
this
review,
we
aim
summarize
up‐to‐date
progression
addressing
various
challenges,
expect
elicit
novel
potential
opportunities
alternatively.
We
first
introduce
sorts
NP
technologies,
illustrate
their
mechanisms,
present
applications.
Then,
achievements
made
by
break
obstacles
delivering
cargoes
specific
sites
through
particular
are
highlighted,
including
long‐circulation,
tumor
targeting,
responsive
release,
subcellular
localization.
subsequently
retrospect
recent
research
treatments
from
single
therapy,
like
chemotherapy,
combination
chemoradiotherapy,
integrative
therapy.
Finally,
perspectives
impact
on
oncology
discussed.
believe
review
can
offer
deeper
understanding